Furthermore, cancers that do not demonstrate mutations in any TGFβ1 signaling cascade members, show down-regulated levels of TGFBR2, demonstrating the oncogenic potential of TGFβ1 pathway [25]. This evidence concerns the gene TGFB1 and cancer.